FibroGen(FGEN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $1.3 million, down from $3.1 million in Q4 2024, representing a decline of approximately 58.1% [23] - For the full year 2025, total revenue was $6.4 million, compared to $29.6 million in 2024, a decrease of about 78.4% [23] - Total operating costs and expenses for Q4 2025 were $14.8 million, up from $10.3 million in Q4 2024 [23] - For the full year 2025, total operating costs and expenses were $52.3 million, significantly reduced from $180 million in 2024 [23] - The net loss for Q4 2025 was $14.6 million, or $3.61 per share, compared to a net loss of $8.7 million, or $2.15 per share in Q4 2024 [25] - The net loss for the full year 2025 was $58.2 million, or $14.40 per share, down from a net loss of $153.1 million, or $38.26 per share in 2024 [25] - As of December 31, the company reported $109.4 million in cash equivalents, investments, and accounts receivable, with a cash runway expected into 2028 [26] Business Line Data and Key Metrics Changes - The company is advancing the FG-3246 program, a potential first-in-class antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer [4][5] - The FG-3246 program is expected to address a significant unmet need in late-stage prostate cancer, with an estimated total addressable market of over $5 billion annually in the U.S. [8] - Roxadustat is being developed for anemia associated with lower-risk myelodysplastic syndromes (MDS), with a significant opportunity due to the lack of oral treatments currently available [18][22] Market Data and Key Metrics Changes - Approximately 290,000 men are diagnosed with prostate cancer each year in the U.S., with about 65,000 drug-treatable patients with metastatic disease that has become castration-resistant [7] - The incidence of grade 3 or greater neutropenia was substantially reduced with the utilization of GCSF prophylaxis in ongoing trials [12] Company Strategy and Development Direction - The company aims to rebrand from FibroGen to Kyntra Bio to better reflect its focus on oncology and rare diseases [7] - The strategy includes advancing mid and late-stage assets and simplifying the capital structure to create value for shareholders [7] - The company is focused on developing FG-3246 and its companion FG-3180 program, with expected interim analysis from the phase 2 monotherapy trial in the second half of 2026 [27] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year, emphasizing the importance of reducing fixed costs to maximize cash runway and invest in U.S. pipeline opportunities [26] - The company remains confident in its positioning to create meaningful therapeutic options for patients and significant value for shareholders [7] Other Important Information - The company has received orphan drug designation for roxadustat, which provides a minimum of 7 years of regulatory exclusivity [22] - The company is exploring opportunities to develop roxadustat internally or with a strategic partner [21] Q&A Session Summary Question: Imaging of CD46 opportunity and commercial potential - Management discussed the potential market for CD46 PET imaging agents and how they would fit into the treatment algorithm alongside existing PSMA agents [30][32] - The company anticipates that patients will need to show positive uptake of CD46 PET imaging to be prescribed FG-3246, similar to the requirements for PSMA agents [34] Question: SUV data and patient selection - Management acknowledged the provocative nature of the SUV data and its potential role in enriching patient selection for treatment [30][40] - The phase 2 trial is designed to define CD46 positivity, which may be based on SUV or other metrics [40] Question: Balance of patients in studies and recruitment - Management clarified that the phase 2 monotherapy trial will focus on patients who have progressed on only one prior ARPI, differentiating it from the IST [46] Question: Updates on roxadustat partnering efforts - Management stated that they are evaluating the opportunity to develop roxadustat internally or through collaboration but did not provide specific updates on the partnering process [49] Question: FDA feedback timeline for roxadustat - Management explained that the FDA indicated a feedback timeline of 60-90 days due to the nature of the protocol submission, which is currently being awaited [53]